These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
162 related articles for article (PubMed ID: 33407760)
1. A comparison of approaches for combining predictive markers for personalised treatment recommendations. Pierce M; Emsley R Trials; 2021 Jan; 22(1):20. PubMed ID: 33407760 [TBL] [Abstract][Full Text] [Related]
2. Integrating biomarker information within trials to evaluate treatment mechanisms and efficacy for personalised medicine. Dunn G; Emsley R; Liu H; Landau S Clin Trials; 2013 Oct; 10(5):709-19. PubMed ID: 24000376 [TBL] [Abstract][Full Text] [Related]
3. A Quantitative Concordance Measure for Comparing and Combining Treatment Selection Markers. Zhang Z; Ma S; Nie L; Soon G Int J Biostat; 2017 Mar; 13(1):. PubMed ID: 28343164 [TBL] [Abstract][Full Text] [Related]
4. Personalised mechanical ventilation tailored to lung morphology versus low positive end-expiratory pressure for patients with acute respiratory distress syndrome in France (the LIVE study): a multicentre, single-blind, randomised controlled trial. Constantin JM; Jabaudon M; Lefrant JY; Jaber S; Quenot JP; Langeron O; Ferrandière M; Grelon F; Seguin P; Ichai C; Veber B; Souweine B; Uberti T; Lasocki S; Legay F; Leone M; Eisenmann N; Dahyot-Fizelier C; Dupont H; Asehnoune K; Sossou A; Chanques G; Muller L; Bazin JE; Monsel A; Borao L; Garcier JM; Rouby JJ; Pereira B; Futier E; Lancet Respir Med; 2019 Oct; 7(10):870-880. PubMed ID: 31399381 [TBL] [Abstract][Full Text] [Related]
5. The Personalised Randomized Controlled Trial: Evaluation of a new trial design. Lee KM; Turner RM; Thwaites GE; Walker AS; White IR Stat Med; 2023 Apr; 42(8):1156-1170. PubMed ID: 36732886 [TBL] [Abstract][Full Text] [Related]
6. Finding the (biomarker-defined) subgroup of patients who benefit from a novel therapy: No time for a game of hide and seek. McShane LM; Rothmann MD; Fleming TR Clin Trials; 2023 Aug; 20(4):341-350. PubMed ID: 37095696 [TBL] [Abstract][Full Text] [Related]
7. Right care, first time: a highly personalised and measurement-based care model to manage youth mental health. Hickie IB; Scott EM; Cross SP; Iorfino F; Davenport TA; Guastella AJ; Naismith SL; Carpenter JS; Rohleder C; Crouse JJ; Hermens DF; Koethe D; Markus Leweke F; Tickell AM; Sawrikar V; Scott J Med J Aust; 2019 Nov; 211 Suppl 9():S3-S46. PubMed ID: 31679171 [TBL] [Abstract][Full Text] [Related]
9. Personalised relaxation practice to improve sleep and functioning in patients with chronic fatigue syndrome and depression: study protocol for a randomised controlled trial. Macnamara CL; Cvejic E; Parker GB; Lloyd AR; Lee G; Beilharz JE; Vollmer-Conna U Trials; 2018 Jul; 19(1):371. PubMed ID: 29996933 [TBL] [Abstract][Full Text] [Related]
10. Treatment allocation strategies for umbrella trials in the presence of multiple biomarkers: A comparison of methods. Ouma LO; Grayling MJ; Zheng H; Wason J Pharm Stat; 2021 Nov; 20(6):990-1001. PubMed ID: 33759353 [TBL] [Abstract][Full Text] [Related]
11. An alternative method to analyse the biomarker-strategy design. Kunz CU; Jaki T; Stallard N Stat Med; 2018 Dec; 37(30):4636-4651. PubMed ID: 30260533 [TBL] [Abstract][Full Text] [Related]
12. Prostate cancer androgen receptor splice variant 7 biomarker study - a multicentre randomised feasibility trial of biomarker-guided personalised treatment in patients with advanced prostate cancer (the VARIANT trial) study protocol. Clark E; Morton M; Sharma S; Fisher H; Howel D; Walker J; Wood R; Hancock H; Maier R; Marshall J; Bahl A; Crabb S; Jain S; Pedley I; Jones R; Staffurth J; Heer R BMJ Open; 2019 Dec; 9(12):e034708. PubMed ID: 31857319 [TBL] [Abstract][Full Text] [Related]
13. Efficacy and cost-effectiveness of an adjunctive personalised psychosocial intervention in treatment-resistant maintenance opioid agonist therapy: a pragmatic, open-label, randomised controlled trial. Marsden J; Stillwell G; James K; Shearer J; Byford S; Hellier J; Kelleher M; Kelly J; Murphy C; Mitcheson L Lancet Psychiatry; 2019 May; 6(5):391-402. PubMed ID: 30952568 [TBL] [Abstract][Full Text] [Related]
14. Personalised medicine in interstitial lung diseases: Number 6 in the Series "Personalised medicine in respiratory diseases" Edited by Renaud Louis and Nicolas Roche. Kokosi MA; Margaritopoulos GA; Wells AU Eur Respir Rev; 2018 Jun; 27(148):. PubMed ID: 29653950 [TBL] [Abstract][Full Text] [Related]
17. Biomarker-guided personalised emergency medicine for all - hope for another hype? Schuetz P; Aujesky D; Müller C; Müller B Swiss Med Wkly; 2015; 145():w14079. PubMed ID: 25695147 [TBL] [Abstract][Full Text] [Related]
18. Auxiliary variable-enriched biomarker-stratified design. Wang T; Wang X; Zhou H; Cai J; George SL Stat Med; 2018 Dec; 37(30):4610-4635. PubMed ID: 30221368 [TBL] [Abstract][Full Text] [Related]
19. Re: Molecular testing to deliver personalised chemotherapy recommendations. Gibbs P; Hong W; Tie J BMC Med; 2023 Sep; 21(1):343. PubMed ID: 37674128 [TBL] [Abstract][Full Text] [Related]
20. Effectiveness of a self-management intervention with personalised genetic and lifestyle-related risk information on coronary heart disease and diabetes-related risk in type 2 diabetes (CoRDia): study protocol for a randomised controlled trial. Davies AK; McGale N; Humphries SE; Hirani SP; Beaney KE; Bappa DA; McCabe JG; Newman SP Trials; 2015 Dec; 16():547. PubMed ID: 26631181 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]